Work

Neoadjuvant erlotinib in stage III NSCLC patients (pts) with activating EGFR mutations (EVENT trial).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.tps7584

Authors: Cengiz Inal, Bilal Piperdi, Steven M. Keller, Balazs Halmos, Mark Stoopler, Sewanti Atul Limaye, Benjamin Philip Levy, Bryan J. Schneider, Mimi Kim, Jessica Sides, Roman Perez-Soler, Haiying Cheng

Institutions: Albert Einstein College of Medicine, Merck & Co., Inc., Rahway, NJ, USA (United States), Montefiore Medical Center, Montefiore Health System, NewYork–Presbyterian Hospital, Columbia University Irving Medical Center, Columbia University, Cornell University, Weill Cornell Medicine

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2597526090

Cites:

Cited by:

Related to: 10